Our Team

Our Team

Management Team

Matt Thompson, M.D.

President and Chief Executive Officer

Matt Thompson, M.D.

President and Chief Executive Officer

Dr. Matt Thompson has been serving as Endologix’ Chief Medical Officer (CMO) since 2016.  In November 2021, Dr. Thompson was appointed President and Chief Executive Officer of Endologix LLC. As CMO Dr. Thompson had oversight of the Company’s business development, medical affairs, regulatory, clinical and R&D departments. Dr. Thompson also led the April 2021 acquisition and subsequent integration of PQ Bypass.

He is also a contract Staff Surgeon, Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation Ohio, and Visiting Professor Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Previously he was the Professor of Vascular Surgery at St George’s, University of London and a Consultant Vascular Surgeon at St George’s Vascular Institute. Dr. Thompson trained at Cambridge, St Bartholomew’s Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Business. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Journal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer reviewed articles and his H-index is 101 (2020).

His clinical interests are in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery.

He has been the clinical director for three London-wide service reconfigurations (cardiovascular disease, major trauma and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.

Cindy Pinto

Chief Financial Officer

Cindy Pinto

Chief Financial Officer

Cindy Pinto was appointed as the Chief Financial Officer in March 2021 after serving as the Interim CFO and principal financial officer since June 2020. During her tenure, she has held various positions in the Finance Department, most recently she was the Vice President, Financial Planning and Analysis. Prior to that, Cindy served as the Company’s Senior Finance Director from February 2016 through September 2018 and as Finance Director from September 2014 through January 2016. Prior to joining Endologix, Cindy served as Finance Director at Covidien. She received a BS in Accounting from Villanova University and an MBA from New York University. During her free time Cindy enjoys hiking, traveling and spending time with her family.

David Saul

Chief Operating Officer and General Counsel

David Saul

Chief Operating Officer and General Counsel

David joined Endologix on the day of incorporation, October 1, 2020 as our General Counsel and soon assumed the role of Chief Operating Officer. Prior to Endologix, David had his own law firm, providing general counsel consulting services to public and private companies in the life sciences industry. Previously, David was a corporate and securities partner with the law firms of Ropes & Gray and with Wilson Sonsini Goodrich & Rosati, focusing his practice on public and private financing and M&A transactions, and on providing general corporate representation to emerging growth life science companies. David has a BA from University of California, Berkeley and a JD from The Law School, University of Chicago. In his free time, David loves to spend time with his wife, children and Rhodesian Ridgeback, and enjoys competing in triathlons.

Richard Mott

Executive Chairman of the Board

Richard Mott

Executive Chairman of the Board

Rich joined Endologix as a member of the Board in June 2020. Upon our incorporation on October 1, 2020, Rich was appointed Executive Chairman of the Board. Rich is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm, which he founded in 2008. Rich served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, from 2002 through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Rich held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company. Rich currently serves on the Board of Directors of several private companies, including Conventis Orthopedics, Sollis Therapeutics, Treace Medical Concepts, Relievant Med Systems, and Arsenal Medical. He is the previous recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award. Rich holds a BS in Ceramic Engineering from Alfred University and is a Graduate of Harvard University's Advanced Management Program.

Vice Presidents

Elisa Hebb

Executive Vice President, Clinical Development & Regulatory Affairs

Elisa Hebb

Executive Vice President, Clinical Development & Regulatory Affairs

Elisa Hebb joined Endologix in August 2018 with more than twenty years of success in Clinical Research and Regulatory Affairs. She has led the development and execution of global clinical studies for both Class II and Class III medical devices in addition to leading regulatory strategies, and submissions for US and international agencies. Elisa comes to us from Spirox/Stryker where she was responsible for Clinical and Regulatory Affairs and was the Compliance Officer.  Previously, Elisa was the Senior Director of Global Clinical Affairs and Clinical Development for Philips Volcano.  Prior vice presidential roles held by Elisa include Atheromed, Crux Biomedical and Apneon. Prior experience is largely in vascular and electrophysiology with such companies as Boston Scientific, Vascular Architects and ACS/Guidant. Elisa earned her Bachelor’s degree from UC Berkeley. She especially enjoys her family, friends, gardening and the fiber arts.

Christopher Leach

Vice President, US Sales

Christopher Leach

Vice President, US Sales

Chris was named VP of US Sales in November 2020 after being at Endologix for eight years. During his tenure he served key management roles, most recently, as a key leader in the business, serving as the Area Sales Director of the Eastern region. Chris has also served as our Director, Global Professional Education and was a Regional Sales Manager at TriVascular prior to the merger with Endologix in 2016. Before joining Endologix, Chris was at Abbott Vascular for twelve years in the peripheral vascular division as a Regional Manager. He has a degree in Biology from Xavier University in Cincinnati. During his free time, Chris spends as much time as possible with his wife and two kids, he is an avid guitarist and has been known to play on a stage or two.

Arif Iftekhar

Vice President, Research & Development

Arif Iftekhar

Vice President, Research & Development

Bio coming soon

Genevieve Dunbar

Vice President, Regulatory Affairs

Genevieve Dunbar

Vice President, Regulatory Affairs

Genevieve was named VP of Regulatory Affairs in December 2021 after being at Endologix for five years. During her tenure she has held various leadership positions in the Regulatory department, most recently as the Senior Director of Regulatory Affairs. Prior to joining Endologix, she held positions of increasing responsibility at Medtronic and Bard Peripheral Vascular. Throughout her career, Genevieve has worked with Class I, II, and III devices with a particular focus on cardiovascular therapies. Her experience encompasses a range of products including transcatheter and surgical heart valves, vena cava filters, peripheral vascular stents, and angioplasty balloons. Genevieve has a BS in Biology from Arizona State University, a MS in Regulatory Affairs from San Diego State University, and holds the Regulatory Affairs Certification via RAPS. During her free time, Genevieve dedicates her time to her family, including her two children, and likes to travel.

Sasha King

Vice President, Human Resources

Sasha King

Vice President, Human Resources

Sasha King joined Endologix in January 2022 as our Vice President, Human Resources. She has served as a leader, bringing over 20 years of experience in Human Resources and is responsible for driving innovative leadership towards the advancement of the Global HR Function in support of the business. Prior to joining Endologix, Sasha worked in various fields including bio-tech, fin-tech, telecommunications, medical devices, and insurance; and has led HR Operations across the globe. Sasha was a key HR leader and business partner at LGC, Ygrene, Calix, Tellabs, AFC, Fireman’s Fund and Medtronic AVE. Sasha is certified with Senior Professional in Human Resources and Society of HR Management – Senior Certified Professional and holds a Bachelor of Science in Human Resource Management.

William Willis

Vice President, Quality

William Willis

Vice President, Quality

William has over 20 years of experience within the medical device industry, having roles within Quality, Regulatory, R&D, and Operations with both start-ups and large corporations. He has extensive experience in transformational leadership, and Quality Management System and product development. Prior to joining, William was Vice President of Quality and Regulatory at Triad Life Sciences where he assisted the company with commercialization of their advanced wound management products. He has held various roles throughout his career with companies such as Becton Dickinson and Medtronic, and previously owned a medical device consulting company specializing in quality, operational management, and regulatory affairs. He has a degree in Mechanical Engineering from the University of Memphis. During his free time, he enjoys spending time with his family, fishing, and restoring classic cars.

Board of Directors

Matt Thompson, M.D.

Matt Thompson, M.D.


Dr. Matt Thompson has been serving as Endologix’ Chief Medical Officer (CMO) since 2016.  In November 2021, Dr. Thompson was appointed President and Chief Executive Officer of Endologix LLC. As CMO Dr. Thompson had oversight of the Company’s business development, medical affairs, regulatory, clinical and R&D departments. Dr. Thompson also led the April 2021 acquisition and subsequent integration of PQ Bypass.

He is also a contract Staff Surgeon, Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation Ohio, and Visiting Professor Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Previously he was the Professor of Vascular Surgery at St George’s, University of London and a Consultant Vascular Surgeon at St George’s Vascular Institute. Dr. Thompson trained at Cambridge, St Bartholomew’s Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Business. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Journal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer reviewed articles and his H-index is 101 (2020).

His clinical interests are in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery.

He has been the clinical director for three London-wide service reconfigurations (cardiovascular disease, major trauma and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.

Richard Mott

Richard Mott


Rich joined Endologix as a member of the Board in June 2020. Upon our incorporation on October 1, 2020, Rich was appointed Executive Chairman of the Board. Rich is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm, which he founded in 2008. Rich served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, from 2002 through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Rich held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company. Rich currently serves on the Board of Directors of several private companies, including Conventis Orthopedics, Sollis Therapeutics, Treace Medical Concepts, Relievant Med Systems, and Arsenal Medical. He is the previous recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award. Rich holds a BS in Ceramic Engineering from Alfred University and is a Graduate of Harvard University's Advanced Management Program.

Sumner Anderson

Sumner Anderson


Sumner Anderson is a Partner on the Public Structured Finance group at Deerfield and joined the Firm in 2012 as a member of the Pharmaceuticals group, providing extensive research and analysis on individual companies operating in the healthcare industry. He transitioned to the Public Structured Finance Group in 2019. Prior to Deerfield, Mr. Anderson was a research analyst covering pharmaceuticals at Millennium Management. Before Millennium, he was a Managing Director in healthcare investment banking at Wells Fargo Securities and a pharmaceutical analyst in Global Equities at Citadel Investment Group. Mr. Anderson’s healthcare investment career has been split between investment banking and equity long short funds. He holds an A.B. in History and Economics from Harvard University, and an M.B.A. with an emphasis in Finance and Accounting from New York University.

Andrew ElBardissi, M.D.

Andrew ElBardissi, M.D.


Andrew ElBardissi, M.D., is a Partner on the Medical Devices team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Taylor Harris

Taylor Harris


Taylor Harris has served as the Chief Financial Officer of MyoKardia since April 2018 which was since purchased in 2020 by Bristol Myers Squibb. Prior to this, from April 2016 to April 2017, he served as senior vice president and Chief Financial Officer of Zeltiq Aesthetics, Inc., a public company that markets the CoolSculpting cryolipolysis system. During that time, he was responsible for the global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company’s commercial operations, including customer service, product support, and inside sales. Zeltiq was acquired by Allergan plc in April 2017. Prior to Zeltiq, Mr. Harris served as Vice President and Chief Financial Officer at Thoratec Corporation, a public company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients worldwide, from October 2012 until October 2015, when the company was acquired by St. Jude Medical, Inc. Mr. Harris joined Thoratec as its senior director of investor relations and business development in February 2010, in which capacity he was responsible for developing and executing the company's investor relations strategy, as well as supporting the company's strategic and business development activities. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a vice president in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a B.A. in physics and economics from the University of North Carolina at Chapel Hill.

Abraham Kometz, M.D.

Abraham Kometz, M.D.


Avi Kometz, M.D., is a Partner on the Medical Devices group at Deerfield and joined the Firm in 2014. Prior to Deerfield, Dr. Kometz was a Partner at Ascent Biomedical Ventures, where he led investment efforts in biotechnology, pharmaceuticals, medical devices and healthcare information technology. Before Ascent, Dr. Kometz served as the head of corporate development at a specialty pharmaceutical company focused on pediatrics. He was also a member of the Healthcare Practice at McKinsey & Company in New York, where he worked on matters including strategy, valuation, organizational change and cost-reduction. Dr. Kometz received his medical doctorate from the University of the Witwatersrand Medical School, South Africa. He began his career as a clinician in South Africa and went on to found and build a group of clinics.

Bryan Sendrowski

Bryan Sendrowski


Bryan Sendrowski is a Partner on the External Operations team at Deerfield and joined the Firm in 2012. He is responsible for the day to day oversight and management of certain investments in Deerfield’s Private Design and Healthcare Innovations Funds. Prior to joining Deerfield, Mr. Sendrowski was Chief Financial Officer of New American Therapeutics, a specialty pharmaceutical company that was funded and facilitated by Deerfield’s Private Design Funds. Before New American Therapeutics, he was Chief Financial Officer at Akrimax Pharmaceuticals and Vice President and Controller of Reliant Pharmaceuticals. He also previously served as a Senior Manager in the financial statement audit practice of KPMG, LLP with responsibility for the management of public and private company audits. Mr. Sendrowski received his B.A. from Pace University and is licensed (inactive) as a Certified Public Accountant in the state of New Jersey.

MM2358 Rev 01